ADGRE3 (Adhesion G Protein-Coupled Receptor E3), also known as EMR3 (Epidermal Growth Factor-like Module-Containing Mucin-like Hormone Receptor-Like 3), is a member of the adhesion GPCR family characterized by a large extracellular region containing multiple epidermal growth factor (EGF)-like domains and a mucin-like stalk. It is predominantly expressed on immune cells, including neutrophils, monocytes, and macrophages, and plays a role in cell-cell adhesion, immune regulation, and inflammatory responses.
ADGRE3 antibodies are tools used to detect and study the expression, localization, and function of this receptor. They have been employed in research exploring its involvement in innate immunity, particularly in neutrophil activation and recruitment during inflammation. Studies suggest ADGRE3 interacts with CD55 on neighboring cells, modulating immune cell interactions and inflammatory signaling. Dysregulation of ADGRE3 has been implicated in diseases like chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, and certain cancers, where its overexpression may influence tumor-associated immune evasion or pro-inflammatory microenvironments.
These antibodies are critical for techniques such as flow cytometry, immunohistochemistry, and Western blotting, aiding in the identification of ADGRE3’s role in pathological and physiological contexts. Recent interest also focuses on its potential as a therapeutic target or biomarker in inflammatory disorders and cancer immunotherapy. However, functional studies remain ongoing to fully elucidate its signaling mechanisms and disease relevance.